JP2005530723A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530723A5 JP2005530723A5 JP2003582175A JP2003582175A JP2005530723A5 JP 2005530723 A5 JP2005530723 A5 JP 2005530723A5 JP 2003582175 A JP2003582175 A JP 2003582175A JP 2003582175 A JP2003582175 A JP 2003582175A JP 2005530723 A5 JP2005530723 A5 JP 2005530723A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- amino acids
- ifnα
- cytokine
- derivative according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000001014 amino acid Nutrition 0.000 claims 12
- 150000001413 amino acids Chemical class 0.000 claims 12
- 102000006992 Interferon-alpha Human genes 0.000 claims 6
- 108010047761 Interferon-alpha Proteins 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000004429 atoms Chemical group 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 2
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 230000000875 corresponding Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010003816 Autoimmune disease Diseases 0.000 claims 1
- 102100016020 IFNG Human genes 0.000 claims 1
- 101700086956 IFNG Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000007306 functionalization reaction Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Claims (14)
- サイトカインに由来し、５〜４０個のアミノ酸を包含するサイズのペプチドであって、上記ペプチドのアミノ酸の少なくとも１個が、上記サイトカインに対応するレセプターの原子から、構造データに基づく評価で、５Å（０．５ｎｍ）未満の距離ｄを隔てた少なくとも１個の原子を有することを特徴とする、但し：
−当該ペプチドは、ｈ ＲＡＮＴＥＳ、ＭＩＰ１α及びＭＩＰ１βの第２及び第３システイン間に含まれる、及び
−当該ペプチドは、ＩＦＮαの第１２３と第１４０アミノ酸の間に含まれる、
前記ペプチド。 - 前記ペプチドの２個の連続するアミノ酸が、前記サイトカインに対応するレセプターの原子から５Å（０．５ｎｍ）未満の距離ｄを隔てた少なくとも１個の原子を有することを特徴とする、請求項１に記載のペプチド。
- 以下のサイトカイン：ＴＧＦβ、ＩＬ１β、ＶＥＧＦ、ＴＮＦα、ＩＦＮα及びγ、ＩＬ４、５、６，１０、１２、１３、１５、１８、２３、ＩＰ１０、ＭＩＰ１α及び１β、並びにＲａｎｔｅｓの断片から選択されることを特徴とする、請求項１または２に記載のペプチド。
- 以下のサイトカイン：ＴＧＦβ、ＩＬ１β、ＶＥＧＦ、ＴＮＦα、ＩＦＮγ、ＩＬ４、５、６、１０、１２、１３、１５、１８、２３の断片から選択されることを特徴とする、請求項１〜３のいずれか１項に記載のペプチド。
- 前記ｄが４Å（０．４ｎｍ）未満であることを特徴とする、請求項１〜４のいずれか１項に記載のペプチド。
- 前記サイトカイン・ペプチドの３または４個の連続するアミノ酸が、前記と同じ間隔基準に合致することを特徴とする、請求項１〜５のいずれか１項に記載のペプチド。
- ３０個未満のアミノ酸を包含することを特徴とする、請求項１〜６のいずれか１項に記載のペプチド。
- 以下のペプチド：
- 前記ペプチドの１個以上のアミノ酸の欠失、置換、付加、環化、（Ｄ体アミノ酸の使用による）立体化学修飾、または（アシル化のような）官能基化によって得られる、請求項１〜８のいずれか１項に記載のペプチド誘導体。
- 請求項１〜９のいずれか１項に記載のペプチドまたはペプチド誘導体を含むが、前記サイトカインの他のエピトープを含まないと理解され、且つ、天然のサイトカインを認識する抗体を被検体内に産生させうることを特徴とする免疫原性化合物。
- ヒトまたは動物の治療法に使用することを目的とする、請求項１〜１０のいずれか１項に記載の、またはＩＦＮαの第１２３と第１４０アミノ酸の間に含まれるペプチドまたはペプチド誘導体、あるいは免疫原性化合物。
- サイトカインの過剰または存在に関連する疾病の治療または予防のための、請求項１〜１０のいずれか１項に記載の、またはＩＦＮαの第１２３と第１４０アミノ酸の間に含まれるペプチドまたはペプチド誘導体、あるいは免疫原性化合物を含む医薬組成物。
- 自己免疫疾病の治療のための、請求項１〜１０のいずれか１項に記載の、またはＩＦＮαの第１２３と第１４０アミノ酸の間に含まれるペプチドまたはペプチド誘導体、あるいは免疫原性化合物を含む医薬組成物。
- 請求項１〜１０のいずれか１項に記載の、またはＩＦＮαの第１２３と第１４０アミノ酸の間に含まれる少なくとも１種類のペプチドまたはペプチド誘導体、あるいは免疫原性化合物を活性成分として含む医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0204464A FR2838444B1 (fr) | 2002-04-10 | 2002-04-10 | Nouveaux peptides et leur application en therapeutique |
| PCT/FR2003/001120 WO2003084979A2 (fr) | 2002-04-10 | 2003-04-09 | Peptides et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530723A JP2005530723A (ja) | 2005-10-13 |
| JP2005530723A5 true JP2005530723A5 (ja) | 2006-05-25 |
Family
ID=28459716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003582175A Pending JP2005530723A (ja) | 2002-04-10 | 2003-04-09 | 新規ペプチド及び治療を目的とするその利用 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US7393523B2 (ja) |
| EP (3) | EP1492814B1 (ja) |
| JP (1) | JP2005530723A (ja) |
| KR (1) | KR101101004B1 (ja) |
| CN (1) | CN1649898A (ja) |
| AT (1) | ATE526985T1 (ja) |
| AU (1) | AU2003260031B2 (ja) |
| CA (1) | CA2480996C (ja) |
| DK (1) | DK2314311T3 (ja) |
| ES (2) | ES2550030T3 (ja) |
| FR (1) | FR2838444B1 (ja) |
| IL (1) | IL164429A0 (ja) |
| MA (1) | MA27191A1 (ja) |
| MX (1) | MXPA04009841A (ja) |
| NZ (1) | NZ536351A (ja) |
| RU (1) | RU2326125C2 (ja) |
| SI (1) | SI2314311T1 (ja) |
| TN (1) | TNSN04200A1 (ja) |
| WO (1) | WO2003084979A2 (ja) |
| ZA (1) | ZA200408451B (ja) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7422743B2 (en) * | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| FR2859725B1 (fr) | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
| CA2557654A1 (en) * | 2004-02-27 | 2005-09-15 | Vaxconsulting | Peptides of il1 beta and tnf alpha and method of treatment using same |
| ZA200802225B (en) | 2005-09-28 | 2009-10-28 | Cytos Biotechnology Ag | Interleukin-1 conjugates and uses thereof |
| NZ592943A (en) | 2008-11-17 | 2012-09-28 | Uinv Kobenhavns | Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases |
| US9301997B2 (en) | 2009-09-21 | 2016-04-05 | Peptinov Sas | Method of vaccination for limiting articular inflammation in rheumatoid arthritis and multiple sclerosis by administering IL-23 peptides |
| EP2569326B1 (en) | 2010-05-11 | 2016-08-10 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Peptide-based inhibitor of interleukin-10 or stat-3 activation |
| CN114966050A (zh) * | 2012-03-18 | 2022-08-30 | 镜株式会社 | 疾病样品分析装置、分析系统及分析方法 |
| JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| EP3302536A1 (en) * | 2015-06-03 | 2018-04-11 | Affiris AG | Il-23-p19 vaccines |
| WO2019074343A1 (ko) * | 2017-10-13 | 2019-04-18 | 주식회사 나이벡 | 고효율 줄기세포 선별을 위한 grp78 유래 펩타이드 |
| CU20210092A7 (es) * | 2019-05-10 | 2022-06-06 | Bimyo GmbH | Péptidos bnip3 para el tratamiento de la lesión por reperfusión |
| WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4772685A (en) * | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
| US5013824A (en) * | 1985-11-19 | 1991-05-07 | Schering Corporation | Human interleukin-4 peptides and conjugates thereof |
| DE3841761A1 (de) * | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
| SK635290A3 (en) * | 1989-12-20 | 1999-06-11 | Schering Corp | Polypeptide, subsequences thereof and their use |
| WO1991014702A1 (en) * | 1990-03-19 | 1991-10-03 | Peptide Technology Ltd. | Anti-tumour peptides |
| FR2677654B1 (fr) * | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
| US6117974A (en) * | 1991-10-02 | 2000-09-12 | Peptor Limited | Libraries of backbone-cyclized peptidomimetics |
| US5494662A (en) * | 1992-04-27 | 1996-02-27 | Ono Pharmaceutical Co., Ltd. | Stimulator for bone formation |
| US5684129A (en) * | 1992-07-07 | 1997-11-04 | Fish; Eleanor N. | Interferon receptor binding peptides |
| US5770191A (en) * | 1995-05-24 | 1998-06-23 | University Of Florida | Active C-terminal peptides of interferon--gamma and their use |
| US5994292A (en) * | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
| CA2279995A1 (en) * | 1997-02-07 | 1998-08-13 | Thomas Jefferson University | Peptide mimetics of the cytokine receptor gamma chain |
| IT1291353B1 (it) * | 1997-05-12 | 1999-01-07 | San Raffaele Centro Fond | Peptidi con attivita' antivirale |
| AU5201399A (en) * | 1997-09-30 | 1999-10-18 | Pharmacia & Upjohn Company | Tnf-related death ligand |
| CA2362264C (en) * | 1999-02-08 | 2012-05-08 | Medvet Science Pty. Ltd. | Cytokine-binding domain |
| EP1156824A2 (en) * | 1999-03-11 | 2001-11-28 | EntreMed, Inc. | Compositions and methods for treating cancer and hyperproliferative disorders |
| US7129072B1 (en) * | 1999-08-30 | 2006-10-31 | New York University | Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor |
| US6420346B1 (en) * | 2000-02-07 | 2002-07-16 | Rappaport Family Institute For Research In The Medical Sciences | Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis |
| WO2002044197A2 (en) * | 2000-12-01 | 2002-06-06 | Fish Eleanor N | Cytokine receptor binding peptides |
| US20030166589A1 (en) * | 2001-06-05 | 2003-09-04 | Nathan Karin | Method and pharmaceutical composition for the treatment of multiple sclerosis |
-
2002
- 2002-04-10 FR FR0204464A patent/FR2838444B1/fr not_active Expired - Lifetime
-
2003
- 2003-04-09 ES ES10183953.8T patent/ES2550030T3/es not_active Expired - Lifetime
- 2003-04-09 EP EP03740584A patent/EP1492814B1/fr not_active Expired - Lifetime
- 2003-04-09 RU RU2004132871/13A patent/RU2326125C2/ru not_active IP Right Cessation
- 2003-04-09 MX MXPA04009841A patent/MXPA04009841A/es not_active Application Discontinuation
- 2003-04-09 DK DK10183953.8T patent/DK2314311T3/en active
- 2003-04-09 CN CNA038100606A patent/CN1649898A/zh active Pending
- 2003-04-09 EP EP10183953.8A patent/EP2314311B1/fr not_active Expired - Lifetime
- 2003-04-09 US US10/510,116 patent/US7393523B2/en not_active Expired - Fee Related
- 2003-04-09 SI SI200332450T patent/SI2314311T1/sl unknown
- 2003-04-09 AU AU2003260031A patent/AU2003260031B2/en not_active Ceased
- 2003-04-09 CA CA2480996A patent/CA2480996C/fr not_active Expired - Fee Related
- 2003-04-09 JP JP2003582175A patent/JP2005530723A/ja active Pending
- 2003-04-09 KR KR1020047016042A patent/KR101101004B1/ko active IP Right Grant
- 2003-04-09 NZ NZ536351A patent/NZ536351A/en not_active IP Right Cessation
- 2003-04-09 AT AT03740584T patent/ATE526985T1/de not_active IP Right Cessation
- 2003-04-09 EP EP10183961A patent/EP2314312A3/fr not_active Withdrawn
- 2003-04-09 ES ES03740584T patent/ES2375053T3/es not_active Expired - Lifetime
- 2003-04-09 WO PCT/FR2003/001120 patent/WO2003084979A2/fr active Application Filing
-
2004
- 2004-10-01 MA MA27884A patent/MA27191A1/fr unknown
- 2004-10-05 IL IL16442904A patent/IL164429A0/xx unknown
- 2004-10-08 TN TNP2004000200A patent/TNSN04200A1/fr unknown
- 2004-10-19 ZA ZA2004/08451A patent/ZA200408451B/en unknown
-
2008
- 2008-06-06 US US12/134,743 patent/US7641895B2/en not_active Expired - Lifetime
-
2009
- 2009-12-01 US US12/628,826 patent/US7892529B2/en not_active Expired - Fee Related
-
2011
- 2011-01-11 US US13/004,588 patent/US8147819B2/en not_active Expired - Fee Related
-
2012
- 2012-01-31 US US13/362,234 patent/US8277792B2/en not_active Expired - Fee Related
- 2012-08-24 US US13/593,823 patent/US8529881B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530723A5 (ja) | ||
| JP2004501101A5 (ja) | ||
| Lehner | Autoimmunity in oral diseases, with special reference to recurrent oral ulceration | |
| JP2005532296A5 (ja) | ||
| WO2006059108A3 (en) | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES | |
| JP2003528155A5 (ja) | ||
| JP2021100937A5 (ja) | ||
| KR101155294B1 (ko) | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 | |
| JP2008501716A5 (ja) | ||
| NZ597915A (en) | Combination therapy for treatment of immune disorders | |
| JP2005537234A5 (ja) | ||
| JP2003526673A5 (ja) | ||
| WO2003090686A3 (en) | Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality | |
| JP2006516116A5 (ja) | ||
| JP2002535285A5 (ja) | ||
| JP2002531421A5 (ja) | ||
| US5859207A (en) | Superantigen agonist and antagonist peptides | |
| JP2003518507A5 (ja) | ||
| US8632781B2 (en) | Immunogenic compounds comprising peptides of IL1β | |
| NZ542866A (en) | Compositions and methods for the therapy of inflammatory bowel disease | |
| JP2006508039A5 (ja) | ||
| JP2004537500A5 (ja) | ||
| JP2004529207A (ja) | Ｌｈｒｈアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療 | |
| RU2004132871A (ru) | Новые пептиды и их применение в терапии | |
| JP2012530755A (ja) | 医薬品 |